Correlation of SARS-CoV-2 to cancer:
Carcinogenic or anticancer? (Review)

YING-SHUANG LI*, HUA-CHENG REN* and JIAN-HUA CAO

Intravenous Drug Administration Center, Department of Pharmacy, The Third People's Hospital of Qingdao, Qingdao, Shandong 266041, P.R. China

Received April 25, 2021; Accepted December 15, 2021

DOI: 10.3892/ijo.2022.5332

Abstract. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly infectious and pathogenic. Among patients with severe SARS-CoV-2-caused by coronavirus disease 2019 (COVID-19), those complicated with malignant tumor are vulnerable to COVID-19 due to compromised immune function caused by tumor depletion, malnutrition and anti-tumor treatment. Cancer is closely related to the risk of severe illness and mortality in patients with COVID-19. SARS-CoV-2 could promote tumor progression and stimulate metabolism switching in tumor cells to initiate tumor metabolic modes with higher productivity efficiency, such as glycolysis, for facilitating the massive replication of SARS-CoV-2. However, it has been shown that infection with SARS-CoV-2 leads to a delay in tumor progression of patients with natural killer cell (NK cell) lymphoma and Hodgkin's lymphoma, while SARS-CoV-2 elicited anti-tumor immune response may exert a potential oncolytic role in lymphoma patients. The present review briefly summarized potential carcinogenicity and oncolytic characteristics of SARS-CoV-2 as well as strategies to protect patients with cancer during the COVID-19 pandemic.

Contents

1. Introduction
2. Tumor viruses
3. Is the SARS-CoV-2 carcinogenic?
4. Patients with COVID-19 with cancer
5. How to protect patients with cancer during the COVID-19 pandemic
6. Oncolytic virus and SARS-CoV-2
7. Conclusion

1. Introduction

Coronaviruses (CoVs) belong to the family Coronaviridae, a member of the order Nidovirales and exist widely in nature (1). Particles of CoVs with a diameter of ~60-220 nm are spherical or oval in shape and display pleomorphism (2,3). CoVs are enclosed by an envelope with spikes and have an internal genome comprising single stranded positive sense RNA (+ssRNA), while being named for their crown- or corona-like viral particles under the electron microscope (2). SARS-CoV-2 has been identified as the seventh coronavirus that is capable of infecting human beings and the remaining six CoVs are HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV and MERS-CoV (1,3-5). Compared with other CoVs, SARS-CoV-2 possesses higher infectivity and pathogenicity because some key sites within the receptor binding domain of spike protein on the surface of SARS-CoV-2 are different from other types of CoVs (3,6,7). In February 2020, the World Health Organization termed SARS-CoV-2-infected pneumonia COVID-19 (8). A great number of patients with severe COVID-19 are either elderly individuals or complicated with other basic diseases. Particularly, patients with malignant tumor are vulnerable to the COVID-19 pandemic due to declined immune function caused by tumor depletion, malnutrition and anti-tumor therapy (9,10). As a result, declined immune function could lead patients with cancer to be more susceptible to COVID-19 and to have a higher chance of developing a severe and critical illness with a poorer prognosis following COVID-19 infection. In addition, SARS-CoV-2 infection may elicit metabolic reprogramming in tumor cells and affect cancer progression (11). Notably, SARS-CoV-2-induced immune response could counteract NK/T cell lymphoma progression to a certain extent (12), suggesting that genetically modified SARS-CoV-2 may exhibit potential oncolytic characteristics. The present review examined the association of SARS-CoV-2 with cancer, providing new ideas to protect patients with cancer during the COVID-19 pandemic.
2. Tumor viruses

What are ‘tumor viruses’? In most cases, virus multiplication in host cells can block protein synthesis and DNA replication of the cells, leading to cell metabolism disorder, while massive replication of virus causes damage to numerous cellular organelles (13,14). After the replication, large numbers of progeny viruses are then released from the cells, resulting in lytic cell death referred to as a destructive process (14,15). Conversely, certain viruses known as ‘tumor viruses’ do not cause the destruction of infected host cells. Instead, tumor viruses can control the complex genome of host cells, promoting unrestricted cell proliferation (13-15). Experiments show that virus infection can successfully induce tumor formation (16,17), showing that tumors can either develop spontaneously in organisms or be formed by virus induction. The above observation has laid a foundation for the following in vitro tumor cell cultures and in vivo transfection in mice. It has been shown that infection of Rous virus leads to the occurrence of tumor cell traits in the cultured cells in vitro, which include a loss of contact inhibition, continued proliferation and anchoring independence (17). To date, several tumor viruses have been identified, including human herpes virus 8 (HHV-8) (18-20), human papilloma virus (HPV) (19,21-27), hepatitis B virus (HBV) (19,28-30), Epstein-Barr virus (EBV) (19,26,31-35), Cytomegalovirus (CMV) (19,27,36-38), human immunodeficiency virus (HIV) (19,39-42), human T cell lymphotropic virus (HTLV) (43,44) and hepatitis C virus (HCV) (45-48) (Fig. 1).

Oncogenic mechanism of tumor viruses. Viruses have a very small genome in which most genes encode proteins involved in virus replication, while only a very small portion of the genes may be related to tumor cell transformation (27). The carcinogenic mechanism of tumor viruses has not yet been fully elucidated, which may be related to the destruction of host cell genetic stability, cell gene phenotype changes and virus latency/reactivation. These mechanisms are not independent and there are complex connections between them. Although different tumor viruses encode different virus products, they can target some of the same mechanisms, such as inhibiting tumor suppressor gene expression, abnormally activating oncogenes to interfere with cell growth and differentiation-related signals including NF-κB, telomerase reverse transcriptase (TERT), tumor necrosis factor receptor associated factors (TRAFs), PI3K-AKT-mTOR, β-catenin and interferon signaling pathway, thereby affecting cell growth cycle regulation and inducing malignant cell transformation (49-51). DNA viruses encode viral oncogenes and RNA viruses can directly encode oncogenes or activate cell oncogenes through cis- or trans activation. Centrifugation-based measurement of the molecular mass of nucleic acids reveals that viral nucleic acid sequences co-sediment with host nucleic acid macromolecules, indicating that viral nucleic acids have become integrated into host chromosomes, constituting the cellular genome (52). It is noteworthy that instead of the whole nucleic acid sequence of viruses, only a part of the sequence with oncogenic role becomes integrated into the cellular genome. In these cases, part of single-strand RNAs in the genome of RNA viruses are reverse-transcribed into double-strand DNAs that are subsequently integrated into host chromosomal DNAs. These integrated viral double-strand DNAs are known as proviruses (53).

The genome of organisms harbors a large number of proto-oncogenes, such as Myc, c-Kit, Raf, Ret, H-ras and K-ras (54-58). Among >30 proto-oncogenes identified to date, most have derived their names from the respective viruses in which they were originally discovered. Once proto-oncogenes in the genome of organisms are captured and activated by the respective viruses, malignant transformation of cells will occur (59). Retroviruses containing oncogenes can capture and activate proto-oncogenes. By contrast, retroviruses without oncogenes activate proto-oncogenes by inserting their own genomes adjacent to those genes (insertion mutations) (60). It has been demonstrated that this insertion is not random and the insertion sites of retrovirus double-strand DNAs (proviruses) are closely adjoined to the proto-oncogenes (60), suggesting the presence of a mechanism underlying the recognition of proto-oncogenes in retroviruses. Under this circumstance, integrated transcriptional promoter of the viral genome causes a damage to the regulatory mechanism of proto-oncogene expression, enabling the expression of cellular genes under the control of the viral promoter and eliciting a constitutive expression of proto-oncogenes (61-63).

In addition to changes in proto-oncogenes and tumor suppressor genes, the origin of tumors also includes the effects on host cell gene stability and gene phenotype. Tumor viruses can inhibit the expression of host tumor suppressor genes and interfere with cell cycle regulation by affecting the form of DNA methylation and histone modification (64,65). In addition, the virus has caused damage to cells before entering the incubation period, resulting in permanent genetic and epigenetic changes in the cells; the virus entering the incubation period may reactivate and cause damage to the cell (64,65). The virus may experience latency/reactivation cycle changes and the cells surviving continuous damage continue to accumulate DNA damage during this period and then a series of effects such as genetic instability, cell immortalization and tumors occur (66).

3. Is the SARS-CoV-2 carcinogenic?

The novel coronavirus SARS-CoV-2 belongs to the β-coronaviruses genus, has an envelope, is 60-140 nm in diameter and round or oval in shape (62). SARS-CoV-2 virus is sensitive to ultraviolet and heat and can be effectively inactivated by heating at 56°C for 30 min or treatment with numerous lipid solvents including ether, 75% ethanol, chlorine containing disinfectant, peracetic acid and chloroform. At present, epidemiological investigation and research reveal that the incubation period of SARS-CoV-2 lasts 1-14 days, generally 3-7 days (67,68). Individuals infected with SARS-CoV-2 are highly infectious 1-2 days before the onset and at the early stage of the disease, while patients infected with SARS-CoV-2 and asymptomatic infected persons are considered the main source of infection (68). Respiratory droplets and close contact transmission have been found to be the main transmission routes. In addition, while contact with virus contaminated items may lead to infection, there is the possibility of aerosol...
transmission under the condition of long-term exposure to high concentration of aerosol in a relatively closed environment (69-71). Given that SARS-CoV-2 has been isolated from feces and urine, attention should be paid to contact or aerosol transmission caused by environmental pollution of feces and urine. SARS-CoV-2 is highly infectious and the total number of infected individuals is now >290 million (71,72). In the meantime, over 5.4 million individuals have succumbed to SARS-CoV-2-caused COVID-19 worldwide (Fig. 2). Similar to tumor viruses, SARS-CoV-2 may accelerate tumor progression by altering the metabolic pathways of tumor cells. It has been shown that SARS-CoV-2 infection of human colon epithelial carcinoma cell line Caco-2 remodels the central cell pathways, including translation, splicing, carbon metabolism and nucleic acid metabolism, while small molecule inhibitors targeting the aforementioned pathways are capable of inhibiting the replication of SARS-CoV-2 in Caco-2 cells (73). For example, nucleic acid metabolism inhibitor Ribavirin can suppress the replication of SARS-CoV-2 at a low molar concentration (73,74). In addition, the proteomics of Caco-2 cells undergo an extensive regulation after 24 h of SARS-CoV-2 infection, which mainly involves a decrease in cholesterol rich metabolic proteins and an increase in carbohydrate metabolism-modifying proteins during the infection (73). Studies imply that SARS-CoV-2 may stimulate metabolism switch in tumor cells to initiate metabolic modes with higher productivity efficiency, such as glycolysis, for facilitating the massive replication of SARS-CoV-2 (75,76). In this case, inhibiting glycolysis metabolism in tumor cells using 2-DG, a hexokinase inhibitor, can significantly suppress the replication of SARS-CoV-2 in Caco-2 cells (73,75). This suggests that SARS-CoV-2 infection may elicit metabolic reprogramming in tumor cells, thereby affecting cancer progression (Fig. 3).

4. Patients with COVID-19 and cancer

The risk of developing a severe illness in patients with COVID-19 complicated with malignancy is 3.61 times as high as that in those without malignancy (77). Recently, epidemiological studies of COVID-19 conducted in New York tertiary health cancer center revealed that 56% of patients with COVID-19 are adults aged ≥60, while the most common malignancies involved include numerous solid tumors such as breast cancer, colorectal cancer and lung cancer (78). Lymphoma is
the most prevalent hematopoietic malignancy and >50% the cases are metastatic solid tumors (78,79). Among patients with cancer and COVID-19, 59% had at least one of the designated complications, including diabetes, hypertension, chronic kidney disease and heart disease (77). Adjuvant therapeutic drugs currently used in clinic include hydroxychloroquine, azithromycin, redcivir, tosilizumab, recovery plasma and corticosteroids (80-84). Patients with hematological cancer and SARS-CoV-2 infection exhibit a higher rate of mortality compared with patients infected with SARS-CoV-2 and with other types of cancer, since malignant or dysfunctional plasma cells, lymphocytes or white blood cells present in hematopoietic malignancies (leukemia, myeloma and lymphoma) can reduce the immune function of organisms (85).

Among all solid tumors, lung cancer has been shown to be the most dangerous class of diseases to patients infected with SARS-CoV-2 (85). For patients with COVID-19 complicated with lung cancer, fever and cough are the most obvious clinical symptoms, while the most significant features of computerized tomography (CT) imaging include ground glass shadow and patchy shadow (85). In addition, laboratory examination reveals that patients with COVID-19 complicated with malignancy, particularly those critical cases, clearly manifest cytokine storm, immune system dysfunction and multiple organ/system damage including a relatively prominent coagulation disorder (86). The risk factors for developing a severe COVID-19 case include old age, IL-6, procalcitonin, increased D-dimer, declined lymphocytes, cancer type, cancer staging and cancer treatment (87-89). According to the data analysis of 7,094 Chinese patients with COVID-19 with an average age of 50, the cancer prevalence in COVID-19 population is 2.3%, which is four times higher compared with that in the entire Chinese population (0.26%) and also three times higher compared with that in the 50-year-old Chinese population (0.39%) (90). This suggests that tumors are closely associated with the risk of severe illness and death in patients with COVID-19. Notably, no difference in the fatality rate or severity of COVID-19 was observed between patients with cancer at an early stage without tumor metastasis and non-cancer patients (85). Conversely, patients with advanced metastatic cancer are more likely to be infected with SARS-CoV-2 (85).

It has also been reported that patients with cancer and COVID-19 display a poor prognosis; this observation was more evident in those with hematological malignancy and a higher risk of death was found in male patients (91). Chemotherapy administered four weeks before the onset of symptoms and being male are considered the high-risk factors for COVID-19 infection in patients with cancer. Among 182 patients with COVID-19 and a complete history of tumor therapy, 31 underwent chemotherapy within 4 weeks prior to being infected with COVID-19 (91). Markedly, the mortality risk of the 31 patients was 3.51 times as high as that of the remaining 151 patients. A relative low mortality was detected in patients with COVID-19 with frequently occurring cancer in women, such as breast cancer, thyroid carcinoma and cervical cancer (91). Conversely, the mortality risk of male patients with cancer infected with COVID-19 was 3.86 times as high as that of the female counterparts (91).

5. How to protect patients with cancer during the COVID-19 pandemic

Postponing targeted therapy or immunotherapy accordingly. Given that patients with cancer and COVID-19 are characterized by high mortality (92), it is recommended that these patients continue to take anticancer drugs orally during the COVID-19 pandemic. However, the antitumor therapy should be undertaken carefully and reasonably, while postponing adjuvant chemotherapy or selective operation needs to be considered on a discretionary basis to avoid the aggravation of pneumonia symptoms (93). In addition, it has been shown that patients with COVID-19 and a history of cancer who are undergoing an active treatment have a higher risk of developing a severe event than those without cancer (94). It is noteworthy that during the hospitalization, the mortality risk of those patients recently undergoing antitumor therapy is 4 times as
high as that of general population (88). In addition, targeted therapy or immunotherapy could lead to a 3.29-fold increase in the risk of developing a severe and critical COVID-19 (88). Notably, among all patients with COVID-19 and cancer receiving various therapies, those undergoing immunotherapy displayed the highest mortality rate as well as the most severe case (88). This increase can be attributed to the enhancement in immune system-mediated attack against SARS-CoV-2 in the later stage of the virus infection, which aggravates the lung damage and then elicits severe symptoms (Fig. 4) (95). In addition, pneumonia accounts for 42% of all death cases caused by the side effects of programmed death-1 (PD-1) antibodies (96). Similarly, either autologous and allogeneic hematopoietic stem cell transplantation or chimeric antigen receptor T cell therapy may lead patients with cancer to be highly susceptible to SARS-CoV-2 infection (88).

By contrast, it has also been demonstrated that blockage of PD-1/PDL-1 pathway can inhibit acute or chronic viral infection to a certain extent. An elderly patient infected with SARS-CoV-2 took nivolumab for metastatic malignant melanoma in the meantime. Surprisingly, considering her age, complications and cancer diagnosis, her virus infection condition was well controlled and no pneumonia was developed (97). This may be attributed to nivolumab-induced blockage of PD-1/PDL-1 pathway and its anti-viral effect.

In addition, use of immune checkpoint inhibitors (ICIs) for the cancer treatment is getting more and more prevalent. However, ICI-caused recovery of immune function in patients...
with cancer may lead to generation of potential lung toxicity, thus aggravating COVID-19 and acute respiratory distress syndrome (ARDS) (98,99). Tocilizumab has been shown to be successfully applied for treatment of the immune-related adverse event (irAE), such as arthritis in patients undergoing ICI treatment (100). As a monoclonal antibody raised against IL-6 receptor, tocilizumab may serve as a potential neutralizing antibody for COVID-19 treatment (95,101,102). Thus, the study of ICI and tocilizumab may provide some new thoughts for overcoming the side effects of irAEs in patients with cancer and COVID-19. In addition, the PD-1 block did not appear to affect the severity of COVID-19 in lung patients with cancer after the risk factors for smoking were excluded (103). Despite all these observations, whether or not ICIs including PD-1 antibody should be given to patients with cancer during SARS-CoV-2 infection needs to be determined based on larger scale clinical analysis, including the perspectives of immune function of patients, tumor type, tumor stage, antiviral efficacy of drugs and so forth. For patients who need to receive cancer treatments, assessment of the immune function of patients based on immune deficiency score index, strengthening nursing care of patients prior to the recovery of immune function and early vaccination against respiratory pathogens, such as seasonal influenza and streptococcus pneumoniae, should be carried out (104).

**Conducting chemotherapy preferentially using drugs with low risk of immunosuppression and oral dosage forms.** During the COVID-19 pandemic, chemotherapy can only be applied to patients with cancer unless immunosuppression, blood toxicity, pneumonia/interstitial lung disease and other serious risks caused by chemotherapy are reduced (94). For example, when chemotherapy regimens with moderate/high risk of immunosuppression (e.g. anthracyclines, docetaxel, cisplatin or carboplatin 3 times a week) are administered to patients with triple-negative breast cancer, it is recommended that the patients should be supplemented with preventive hematopoietic growth factors to reduce the risk of suffering from neutropenia (105). Application of steroids needs to be strictly controlled to prevent an increased risk of immunosuppression. During the pandemic, the oral preparation is usually the first choice for adjuvant bisphosphonates. Low-dose oral medication such as capecitabine and vinorelbine should be considered preferentially in choosing the chemotherapy regimen for avoiding hematological toxicity (94). In case intravenous injection is considered

---

Figure 4. Potential immune risks associated with the application of PD-1 antibodies to treat patients with cancer complicated with a severe COVID-19. Administration of PD-1 antibodies to patients with cancer and severe COVID-19 for an antitumor therapy may result in increased attack against the host cells harboring the viral components due to the activated immune system and even initiate the cytokine storm, thereby promoting inflammation and lung toxicity. COVID-19, coronavirus disease 2019; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; PD-1, Programmed death-1.
unavoidable, preferential use of liposome preparation of anthracyclines and prolonged dosing interval of intravenous injection should be applied.

**Employing hypofractionated radiotherapy (RT-hypo) or short fractionated radiotherapy to treat non-metastatic cancer.**

It has been suggested that during the COVID-19 outbreak, RT-hypo can be applied for the treatment of neck squamous cell carcinoma (HNSCC) patients with a relatively lower risk of distant metastasis (106). It is proposed that RT-hypo be considered in place of concurrent chemoradiotherapy for HPV+T1-T3N0-N2c (TNM-7) HNSCCs, HPV-T1-T2N0 HNSCCs and selected stage III HNSCCs during the outbreak (106). When shorter and fewer hospital visits, as well as avoidance of immunosuppressive chemotherapy, are needed to reduce the risk of SARS-CoV-2 infection, RT-hypo or short fractionated radiotherapy may provide a more appropriate regimen for patients with non-metastatic cancer. Therefore, it is necessary to assess the risk of disease progression for those patients who do not receive a timely and effective antitumor therapy. In this case, a timely diagnosis and tumor treatment should be applied to those patients with a rapidly progressed cancer such as lung cancer, pancreatic cancer, leukemia and highly invasive lymphoma. By contrast, targeted tumor therapy may be postponed for patients with thyroid carcinoma, breast cancer, or other carcinoma at a relatively low risk of disease progression. Particularly, for hospitalized elder tumor patients with COVID-19 or patients complicated with other basic diseases, early clinical monitoring should be strengthened, while timely and effective tumor intervention measurements need to be formulated. If possible, priority should be given to minimally invasive surgery because compared with open surgery, minimally invasive surgery can shorten the duration of hospitalization and improve the recovery of patients with cancer, thereby reducing the risk of SARS-CoV-2 infection in hospital (67).

**Downregulating the expression of TMPRSS2 through inhibiting androgen receptor signaling.**

Some evidence suggests that therapeutic drugs for prostatic cancer may serve a synergistic role in treating COVID-19 (107). Inhibition of androgen signaling is considered the symbolic therapeutic strategy of prostatic cancer, while androgen inhibitors (e.g. leuprolide) and androgen receptor (AR) signaling inhibitors (e.g. enzalutamide, apalutamide and darolutamide) constitute the basis for the treatment of prostate cancer (107). In particular, either inhibition of AR expression and transcription or blockade of CYP17 by abiraterone provide a new perspective for the treatment of hormone-independent prostatic cancer (107). Transmembrane serine protease 2 (TMPRSS2) and angiotensin-converting enzyme 2 (ACE2) have been identified as the key targets for enhanced entry of SARS-CoV-2 into host cells (72,108,109). In addition, AR signaling has been demonstrated to promote the expression of TMPRSS2 (107). Thus, inhibition of AR signaling for treating prostatic cancer may suppress infection of SARS-CoV-2 in host cells by downregulating TMPRSS2, thereby preventing and treating COVID-19 (Fig. 5). However, preclinical studies have demonstrated that while inhibition of AR decreases the expression of TMPRSS2, it may lead to an upregulation in the expression of ACE2, increasing the risk of SARS-CoV-2 infection (107). Therefore, the potential negative outcome caused by inhibition of AR needs to be further evaluated.

**Downregulating the expression of ACE2 using ACE inhibitors (ACEIs).**

It has been reported that patients with various cardiovascular diseases, diabetes or hypertension have an elevated level of ACE2, while displaying a relatively high risk of dying from COVID-19 (110). Notably, the expression level of ACE2 in kidney is higher than that in other organs; the level in kidney can be 100 times as high as that in lung (110). Thus, studies on shared molecular markers and overlapping signaling pathways between renal cell carcinoma (RCC) and COVID-19 will be of great clinical significance for the treatment of RCC patients complicated with COVID-19. Administration with ACEIs can reduce the tumor growth and metastatic potential, prolonging the survival period of patients with RCC. In addition, ACE2 inhibition leads to decreased ACE2 available for binding with the viruses (111-113), probably reducing the susceptibility of patients with RCC to SARS-CoV-2. Likewise, inhibition of ACE2 in other types of malignancies can effectively block the entry of SARS-CoV-2 into host cells. Cancer cells in general express higher levels of ACE2 compared with their adjacent normal cells and thus can be potentially more susceptible to SARS-CoV-2 infection (3). Since cancer cells have managed to evade host immune response in the first place, this may provide a better microenvironment for SARS-CoV-2 replication in
cancer cells/tissues, which may partly explain why patients with cancer seem to be more susceptible to SARS-CoV-2 infection (87). Although ACEI-caused decline in bradykinin degradation may stimulate the growth, survival and migration of cancer cells, these effects can be finally counteracted by decreased expression of VEGFs due to ACEI-caused reduction in Ang II level and angiogenesis (110).

**Strengthening anticoagulant prevention and treatment of diseases at early stage.** It has been shown that the expression of tissue factor in tumor cells can promote tumor growth and angiogenesis, thereby resulting in release of coagulant particles into circulation system, which subsequently triggers thromboembolism in patients with cancer (114). Given that concomitant infection with COVID-19 and hypoxia in patients with cancer lead to a higher risk of developing a thrombotic event, anticoagulant therapy could serve as one of preventive and treatment strategies for patients with cancer and infected with COVID-19 (115). It is thought that early administration of heparin can defer the dramatic increase of inflammatory biomarkers and downregulate coagulation state. A retrospective study conducted in China investigated 449 patients with severe COVID-19, among which 272 suffered from one or more chronic underlying diseases such as hypertension and heart diseases. In that study, patients underwent the treatment with various forms of heparin and a relatively lower mortality rate was observed in patients treated with heparin (40% vs. 64.2%, P=0.029) (116). Similarly, statins with anti-inflammatory, anti-thrombotic and immunomodulatory effects may reduce the risk of cardiovascular complications and thromboembolic events in patients with COVID-19 (117). In addition, ACEI, angiotensin receptor blockers, CCR5 treatment (118-120), tyrosine kinase inhibitors (TKIs) (121-125), bevacizumab (126,127), tensin receptor blockers, CCR5 treatment (118-120), tyrosine kinase inhibitors (TKIs) (121-125), bevacizumab (126,127), ruxolitinib (126,128), camofur (126,129) and toremifene (126,130) could potentially be used as cancer therapy regimens aimed at counteracting COVID-19 mechanistically (Table I).

**Supplementing intestinal probiotics.** Notably, SARS-CoV-2 RNAs have been detected in the feces of certain patients with COVID-19 (131). Thus, diversity of intestinal flora and the presence of intestinal probiotics may serve an important role in assessing the disease course of COVID-19 (132). Patients with cancer usually display a compromised immune function as well as general imbalance of intestinal flora, which are very likely to aggravate the clinical manifestation of COVID-19 (132). Therefore, the recovery of patients with cancer infected with SARS-CoV-2 could be promoted by the administration of effective probiotics (e.g., fructooligosaccharide (FOS), galactooligosaccharides (GOS) and various Lactobacillus strains), which are selected based on analysis of intestinal flora in these patients. Alternatively, patients with cancer can take special probiotics for improving intestinal dystrophy, enhancing immunity and preventing against SARS-CoV-2 infection. Studies on effects of SARS-CoV-2 on the intestinal ecosystem in patients with cancer will provide new ideas for preventing and controlling the viral infection of patients with declined immunity such as patients with cancer.

Regularly supplementing vitamin and micronutrients. Vitamin D is a fat-soluble vitamin that can be obtained from the diet, the classic role of which is to promote bone remodeling (133). Serum levels of 25-hydroxyvitamin D [25 (OH) D] have been shown to be negatively associated with a higher risk of colon, breast, prostate, stomach and other cancers (134). Vitamin D deficiency has been proved to contribute to the occurrence and progression of a number of cancers, so maintaining adequate serum vitamin D levels may be beneficial for cancer prevention and treatment (134). Recent studies have reported a significant association between the average level of vitamin D and the number of patients with COVID-19, especially the mortality rate (133,135-137). Vitamin D deficiency is present in >80% of patients with severe COVID-19 and is associated with poor prognosis (133,136). Vitamin D deficiency may contribute to the exacerbation of COVID-19 through inducing thrombotic effects and immune dysregulation (136). In immune response, vitamin D-dependent antimicrobial pathways are known to respond to double-stranded RNA produced in replication processes of SARS-CoV-2 (136,138). These pathways subsequently upregulated the autophagy of damaged cells, as well as levels of various antimicrobial and antiviral peptides (136,138). Thus, vitamin D deficiency may predispose a host to SARS-CoV-2 infection by blocking the activation of above defense pathways and the migration of lymphocytes and macrophages (136). These findings suggest that vitamin D may protect the body from acute respiratory infections, while elderly patients with cancer and extreme vitamin D deficiency may be more susceptible to COVID-19. In addition to vitamin D, adequate levels of vitamin C and E are also essential to reduce the burden of symptoms and shorten the duration of respiratory infections during the COVID-19 pandemic (137). Micronutrients such as selenium and zinc, the dietary supplements in multivitamin tablets, not only serve important roles in cancer progression and therapy, but can also increase the immune responses against viral infection (138,139). It is speculated that selenium and zinc may also have a potential inhibitory effect on COVID-19 infection (137,138). Thus, regular supplementation of vitamin and other micronutrients may improve severe COVID-19 symptoms and survival in elderly patients with cancer. However, it is worth noting that further research is needed to determine the effective dose of vitamin and micronutrients supplements to help patients with cancer alleviate the symptoms of COVID-19.

**The COVID-19 vaccination policies for patients with cancer.** At present, there are differences in the COVID-19 vaccination policy for patients with cancer. In some countries, the COVID-19 vaccine is not recommended for patients with malignant tumors, or even as a contraindication for vaccination (140). The main reason is the lack of clinical data on COVID-19 vaccine for patients with cancer, so the safety status, effectiveness and immune response after vaccination cannot be evaluated. However, recent reports show that even for patients with cancer, if there are no contraindications to the vaccine components, they may still receive COVID-19 vaccination and get sufficiently high immunogenicity (141-143). Although patients with cancer may have a delayed response to the vaccine, it may still bring some benefits, which is important for reducing the risk or severity of SARS-CoV-2 patients with...
Table I. Potential and risk of drugs to improve symptoms of patients with cancer and COVID-19.

| Author, year          | Drugs                                      | Targets      | Mechanisms of anticancer and antiviral                                                                 | Types of cancer treated                                                                 | Risk                          | (Refs.)         |
|-----------------------|--------------------------------------------|--------------|-------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-------------------------------|-----------------|
| Luo et al, 2020       | Combination therapy of ICI and PD-1/CTLA-4  | IL-6         | Activating the immune system; Reducing the risk of immune-related adverse events caused by immunotherapy and viral infection | Lung cancer, stomach cancer, bowel cancer, liver cancer, kidney cancer, bladder cancer, head and neck squamous cell carcinoma, cervical cancer, hodgkin lymphoma, mediastinal diffuse large B-cell lymphoma, Merkel cell carcinoma and other solid tumors | Cytokine storms              | (83, 97, 100-103) |
| Yekedüz et al, 2020   | Therapy of IL-6                            |              |                                                                                                       |                                                                                        |                               |                 |
| Presti et al, 2021    | Tocilizumab/ Sarilumab                     |              |                                                                                                       |                                                                                        |                               |                 |
| Klopfenstein et al, 2020 | Tocilizumab/ Sarilumab                |              |                                                                                                       |                                                                                        |                               |                 |
| Toniati et al, 2020   | ICI and Tocilizumab/ Sarilumab            |              |                                                                                                       |                                                                                        |                               |                 |
| Luo, 2020             |                                             |              |                                                                                                       |                                                                                        |                               |                 |
| Mihalopoulos et al, 2020 | ACEI/ARB ACE; AIIR                     |              | Antagonizing tumor growth and reducing cancer incidence by reducing Ang II production; Alleviating acute lung injury and reducing risk of lung failure | Prostate cancer and advanced ovarian cancer                                                                 | Rebound ACE2 receptor upregulation may increase the risk of viral infection | (110-113)        |
| Li et al, 2020        |                                             |              |                                                                                                       |                                                                                        |                               |                 |
| Rico-Mesa et al, 2020 |                                             |              |                                                                                                       |                                                                                        |                               |                 |
| De Spiegeleer et al, 2020 | Statins HMG-CoA reductase               |              | Reducing TC and LDL levels; anti-tumor proliferation; pro-tumor apoptosis; anti-tumor invasion and radiosensitization; reducing inflammation in patients with pneumonia | Prostate cancer, glioma, esophageal cancer, stomach cancer, colon cancer, breast cancer, ovarian cancer, endometrial cancer and kidney cancer | Long-term use may increase the risk of invasive ductal carcinoma and lobular carcinoma | (113,117)        |
| De Spiegeleer et al, 2020 |                                             |              |                                                                                                       |                                                                                        |                               |                 |
| Lee et al, 2020       |                                             |              |                                                                                                       |                                                                                        |                               |                 |
| Aldinucci et al, 2020 | Maraviroc// Vicriviroc Leronlimab         | CCR5         | Increasing CD4/CD8 ratios; promoting the conversion of TAMs from M2 to M1; down-regulating chemokines and cytokines stimulating tumor growth; improving inflammatory microenvironment around tumor; Decreasing inflammatory cytokines and SARS-CoV-2 RNA in plasma | Metastatic colorectal cancer and breast cancer                                                                 | Uncertain                     | (118-120)       |
| Patterson et al, 2021 |                                             |              |                                                                                                       |                                                                                        |                               |                 |
| Patterson et al, 2020 |                                             |              |                                                                                                       |                                                                                        |                               |                 |
| Wang et al, 2019      |                                             |              |                                                                                                       |                                                                                        |                               |                 |
| Choueiri et al, 2020  | Sunitinib                                  | AAK1, VEGF   | Anti-tumor angiogenesis; inhibiting virus invasion and transport in host cells                                                                 | Advanced hepatocellular carcinoma and renal cell carcinoma                                                                 | Cardiotoxicity caused by off-target effects | (121-123)       |
| Aeppli et al, 2020    |                                             |              |                                                                                                       |                                                                                        |                               |                 |
| Wang et al, 2019      |                                             |              |                                                                                                       |                                                                                        |                               |                 |
| Author(s)          | Year | Drugs                        | Targets                          | Mechanisms of anticancer and antiviral                                                                 | Types of cancer treated                              | Risk       | Refs.       |
|-------------------|------|------------------------------|---------------------------------|--------------------------------------------------------------------------------------------------------|------------------------------------------------------|------------|-------------|
| El Bairi et al.   | 2020 | Bevacizumab                  | VEGF                            | Anti-tumor angiogenesis; inhibiting tumor cell proliferation and survival by blocking abnormal activation of JAK-STAT signal; suppressing excessive immune activation; dampening the cytokine storm and improving ARDS caused by COVID-19 | Advanced ovarian cancer, renal cell carcinoma and colorectal cancer | Leukopenia and thromboembolism | (126,127)  |
| Pang et al.       | 2021 | Erlotinib                    | AAK1, EGFR                       | Anti-tumor angiogenesis; promoting tumor cell apoptosis; inhibiting virus invasion and transport in host cells | Metastatic EGFR-mutant non-small cell lung cancer | Uncertain  | (124,125)  |
| Abdelgalil et al. | 2020 | Erlotinib                    | AAK1                              | Inhibiting tumor cell proliferation and survival by blocking abnormal activation of JAK-STAT signal; suppressing excessive immune activation; dampening the cytokine storm and improving ARDS caused by COVID-19 | Metastatic EGFR-mutant colorectal cancer | Various myeloproliferative malignancies including myelofibrosis and myeloproliferative vera | (126,128)  |
| Birk et al.       | 2020 | Erlotinib                    | AAK1, EGFR                       | Inhibiting tumor cell proliferation and survival by blocking abnormal activation of JAK-STAT signal; suppressing excessive immune activation; dampening the cytokine storm and improving ARDS caused by COVID-19 | Metastatic EGFR-mutant non-small cell lung cancer | Various myeloproliferative malignancies including myelofibrosis and myeloproliferative vera | (126,129)  |
| El Bairi et al.   | 2020 | Ruxolitinib                  | JAK-STAT pathway                 | Inhibiting tumor cell proliferation and survival by blocking abnormal activation of JAK-STAT signal; suppressing excessive immune activation; dampening the cytokine storm and improving ARDS caused by COVID-19 | Metastatic EGFR-mutant colorectal cancer | Various myeloproliferative malignancies including myelofibrosis and myeloproliferative vera | (126,128)  |
| Stebbing et al.   | 2020 | Carmofur                     | Wnt/β-catenin signaling pathway  | Exciting anti-proliferative and anti-metastatic effects by blocking the Wnt/β-catenin signaling pathway; inhibiting the viral protease of SARS-CoV-2 through the covalent binding between the catalytic Cys145 and the viral NSP14 and SARS-CoV-2 | Uncertain (126,129) | Various myeloproliferative malignancies including myelofibrosis and myeloproliferative vera | (126,130)  |
| Jin et al.        | 2020 | Combination therapy of Tamoxifen and emodin | Oestrogen receptors: NSP-14, Wnt/β-catenin signaling pathway | Inhibiting the viral protease of SARS-CoV-2 through the covalent binding between the catalytic Cys145 and the viral NSP14 and SARS-CoV-2 | Breast cancer | Various myeloproliferative malignancies including myelofibrosis and myeloproliferative vera | (126,130)  |
cancer (141,142). However, certain treatments for cancer, such as chemotherapy or immunotherapy, can weaken the immune system and may increase the risk of COVID-19 infection (144). Therefore, patients with early malignant tumors who have completed radical treatment and are not receiving anti-tumor therapy, can be vaccinated with COVID-19 vaccine; for patients with malignant tumors who are receiving chemotherapy, targeted therapy or immunotherapy, the vaccine should be used with caution; for patients with malignant tumors who are receiving endocrine therapy, the vaccine can be given to those in good health, while is not recommended for patients in poor health, whether or not they are receiving anti-tumor therapy (141,145). In the case of breast cancer, inactivated vaccines are recommended during breast cancer rehabilitation, including endocrine therapy and HER2 targeted therapy; whereas for patients undergoing surgery, chemotherapy and PD-1 treatment, it is recommended to wait for the sufficient clinical evidence to prove the safety and effectiveness before vaccination. For patients with cancer and impaired immune function, it is recommended to vaccinate live attenuated vaccines and recombinant subunit vaccines; and it is recommended to weigh the benefit and the risk before vaccinating with adenovirus vector vaccines (142). Notably, due to the low immune function, the degree of immunity of patients with cancer after vaccination is still uncertain. Patients with cancer vaccinated should continue to follow current guidance to avoid COVID-19 infection.

6. Oncolytic viruses and SARS-CoV-2

Oncolytic viruses. Oncolytic viruses are a class of natural or genetically-modified viruses that are capable of self-replicating and killing cancer cells (146). After infecting cancer cells, oncolytic viruses will replicate massively in the cells and promote the lytic cell death during the replicative process (Fig. 6) (146-149). At present, the latest clinical regimen for
combined therapy of oncolytic viruses involves a combination with PD-1/PD-L1 antibodies, providing effective and individualized tumor specific oncolytic immunotherapy to patients with cancer who are resistant to PD-1/PD-L1 blockade therapy (149,150). Notably, it has been shown that oncolytic viruses can trigger antiviral response of the immune system to increase the level of interferons in the tumor environment, thereby promoting PD-L1 production for the immune evasion (Fig. 7) (149).

Does SARS-CoV-2 display potential oncolytic characteristics? It has been shown that ACE2 serves as a key target for SARS-CoV-2 infection of host cells (3,110). As NK cells massively express ACE2, they are easily infected by SARS-CoV-2, resulting in a decline in cell numbers as well as loss of immune function (151). Certain RNA viruses causing acute pulmonary infection have been found to promote apoptosis in NK cells (12). Notably, elevated levels of IL-6 and IL-10 caused by SARS-CoV-2 infection lead to a marked decrease in the cytotoxicity of NK cells, while SARS-CoV-2-induced release of IL-2 and TNF-α recruits NK and T cells into the tumor tissue (12). Based on the above observations, it is hypothesized that excessive production of proinflammatory cytokines during COVID-19 infection may serve a pivotal role in lymph node clearance. The depletion and inactivation of NK cells could serve as a therapeutic regimen for NK lymphoma patients who are resistant to conventional chemotherapy and improve the signs and clinical symptoms of the patients with cancer. In addition, the viral copy number of EBV-DNA, a sensitive biomarker of NK/T cell lymphoma, has been shown to be markedly declined during the course of COVID-19 (12). In addition, serum copy number of EBV-DNA, cell number of NK cell clones and recurrence rate of lymphoma in patients with NK lymphoma are increased.
after the subsiding of SARS-CoV-2 infection (12), indicating that COVID-19 infection can defer the tumor progression of NK lymphoma patients. The binding between SARS-CoV-2 and the respective receptors such as ACE2 in NK cells may determine its targeting of oncolytic adenoviruses. All these observations suggest that while SARS-CoV-2-induced immune response exerts an anti-tumor effect to a certain extent, SARS-CoV-2 displays potential oncolytic characteristics for lymphoma patients.

In addition, recent studies have suggested that SARS-CoV-2 infection may protect against Hodgkin's lymphoma by eliciting an anti-tumor immune response (149). Shortly after having been diagnosed with advanced Hodgkin's lymphoma, a 61-year-old man with severe kidney disease who was on long-term dialysis had been confirmed with COVID-19 infection (149). After 11 days hospitalization, he was discharged and returned home for rehabilitation. No corticosteroids or immunosuppression or chemotherapeutic drugs with low risk of toxicity and metabolic disorders caused by chemotherapy and immunosuppressive agents. At present, studies provide evidence that combination therapy with oncolytic vaccine and toxoid can help initiate anti-tumor immune response of the immune system via CD4+ memory T cells. Therefore, if oncolytic responses of SARS-CoV-2 may cover cross reactions between pathogen-specific T-cells and tumor antigens and the activation of natural killer cells through inflammatory cytokines generated during response to the infection of SARS-CoV-2. In addition, the majority of tumor patients suffer from nephropathy, diabetes and other complications and oncolytic virus therapy can partially offset the hepatorenal toxicity and metabolic disorders caused by chemotherapy and immunosuppressive agents. At present, studies provide evidence that combination therapy with oncolytic vaccine and toxoid can help initiate anti-tumor immune response of the immune system via CD4+ memory T cells. Therefore, if oncolytic characteristics of SARS-CoV-2 could be combined with the memory of T cells by genetic modification to recall the immunity of known antigens to coronavirus, this scenario may provide a new approach for the genetic modification of oncolytic viruses.

7. Conclusion

SARS-CoV-2 may affect tumor progression through multiple mechanisms, including glycolysis, translational modification, nucleic acid synthesis, lipid metabolism and transcriptional splicing. Patients with cancer complicated with COVID-19 have a greater chance of developing a severe and critical illness as well as a poorer prognosis. Given that immunopotentiation therapies such as ICI and CAR-T used for tumor treatment could aggravate inflammatory symptoms of patients with COVID-19, targeted therapy or immunotherapy should be postponed accordingly based on risk of disease progression. While either chemotherapeutic drugs with low risk of immunosuppression or short fractionated radiotherapy can be preferentially applied to non-metastatic patients with cancer or those with cancer at early stage; administration with high selective inhibitors targeting for TMPRSS2 or ACE2 might be a feasible regimen for protecting advanced patients with cancer against SARS-CoV-2 infection. In addition, regular supplementation of vitamin and other micronutrients may improve severe COVID-19 symptoms and survival in elderly patients with cancer. The correlation of dynamic changes of COVID-19 antibody, nucleic acids, tumor metabolism pathway switch and levels of tumor-related cytokines with the prognosis during the disease course of patients with cancer is worthy of further study. Given SARS-CoV-2-activated anti-tumor immune response and its toxic inhibitory effect on NK cells, SARS-CoV-2 may possess potential oncolytic characteristics in lymphoma patients. Therefore, genetic modification of SARS-CoV-2 and in-depth studies of immune-stimulating mechanism may provide more new directions for oncolytic virotherapy.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

Data sharing is not applicable to this article, as no data sets were generated or analyzed during the current study.

Authors’ contributions

YSL conceived the study and wrote the manuscript. HCR summarized and analyzed the data and produced graphs. JHC contributed to the critical reading and correction of the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Hartenian E, Nandakumar D, Lari A, Ly M, Tucker JM and Glaunsinger BA: The molecular virology of coronaviruses. J Biol Chem 295: 12910-12934, 2020.
2. Mortaz E, Tabarsi P, Varahram M, Folkerts G and Adcock IM: The immune response and immunopathology of COVID-19. Front Immunol 11: 2037, 2020.
3. Tan HW, Xu YM and Lau ATY: Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection. Rev Med Virol 30: e2122, 2020.
4. Ye ZW, Yuan S, Yuen KS, Fung SY, Chan CP and Jin DY: Zoonotic origins of human coronaviruses. Int J Biol Sci 16: 1686-1697, 2020.
5. Chang L, Yan Y and Wang L: Coronavirus disease 2019: Coronavirus and blood safety. Transfus Med Rev 34: 75-80, 2020.
6. Cui X, Sun X, Ye J, Ding L, Liu M, Yang Z, Lu X, Zhang Y, Ma L, Gu W, et al: Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol Immunol 17: 621-630, 2020.
7. Yuan M, Wu NC, Zhu X, Lee CD, So RTY, Lv H, Mok CKP and Wilson IA: A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368: 630-633, 2020.
8. Jiang S, Hillery C and Du L: Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol 35: 330-340, 2020.
9. van Dam PA, Huizing M, Mestach G, Dierckxsens S, Tjala W, Trinh XB, Papadimitriou K, Alintas T, Vermerkorn J, Vulturke C, et al: SARS-CoV-2 and cancer: Are they really partners in crime? Cancer Treat Rev 89: 102068, 2020.
10. Garrone O, Denaro N, Ruatta F, Vanella P, Granetto C, Vandone AM, Occelli M, Cauchi C, Ricci V, Fea E, et al: Treating patients with cancer amidst the COVID-19 pandemic: Experience of a regional hospital in the Piedmont region in northern Italy. Tumori 106: 427-431, 2020.
11. Bokharaei-Salim F, Mirzaei H and Hamblin MR: Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer. Curr Opin Virol 37: 37-43, 2019.
12. Akram N, Imran M, Noreen M, Ahmed F, Atif M, Fatima Z and Bilal Waqar A: Oncogenic role of tumor viruses in humans. Viral Immunol 30: 20-27, 2017.
13. White MK, Pagano JS and Khalili K: Viruses and human cancers: A long road of discovery of molecular paradigms. Clin Microbiol Rev 27: 463-481, 2014.
14. Kuss-Duerkop SK, Weistrich JA and Pyeon D: DNA tumor virus transformation through both lipopolysaccharide and flagellin. Curr Opin Oncol 32: 122-128, 2020.
15. Dupin N and Deleuze J: Kaposi sarcoma and HHV-8: A model of cutaneous cancer in immunosuppressed patients. Rev Prat 64: 311-316, 2014 (In French).
16. Stern J, Miller G, Li X and Saxena D: Virome and bacteriome: Is there a coin. Curr Opin Virol 37: 37-43, 2019.
17. Emi Et, Alayande DP, Mavhundu-Ramarumo LG, Gachara G and Bessong PO: HHV-8 seroprevalence and genotypetype distribution in Africa, 1998-2017: A systematic review. Viruses 10: 458, 2018.
18. Ruslan M, Li YY and Hammerman PS: Genomic landscape of human papillomavirus-associated cancers. Clin Cancer Res 21: 2009-2015, 2015.
19. Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imai-Rosshandler I, Pugh TJ, Cherniack AD, Ambrogio L, Cibulskis K, Bertelsen B, et al: Landscape of genomic alterations in cervical carcinomas. Nature 506: 371-375, 2014.
20. Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EA, Wilkerson MD, et al: Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci USA 111: 1544-1549, 2014.
21. Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, Sundström K, Dillner J and Sparén P: HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 383: 1340-1348, 2020.
22. Sadri Nahand J, Moghfoori M, Salanmiejad A, Bahnpouran Z, Karimzadeh M, Nasiri M, Mirzae H, Pourhassel MH, Bokharaei-Salim F, Mirzaei H and Hamblin MR: Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review. Int J Cancer 146: 305-320, 2020.
23. Chen J, Kendrick S and Qin Z: Mechanistic insights into chemoresistance mediated by oncogenic viruses in lymphomas. Viruses 11: 1161, 2019.
47. Huang P, Wang CH, Zhuo LY, Xia XS, Yang S, Zhang JW, Fan HZ, Wu JJ, Yu R, Yue M and Zhang Y: Polymorphisms rs763110 in FASL is linked to hepatitis C virus infection among high-risk populations. Br J Biomed Sci 77: 112-117, 2020.

48. De Francesco I, Zerbi C, Raittoli S, Merli M, Bruno R, Paulli M and Arculli L: HCV infection and non-Hodgkin lymphomas: An evolving story. Clin Exp Med 20: 321-328, 2020.

49. Elgui de Oliveira D: DNA viruses in human cancer: An integrated overview on fundamental mechanisms of viral carcinogenesis. Viruses 12: 182-206, 2020.

50. Fujimuro M, Wu FY, ApRhyx C, Kajumbula H, Young DB, Hayward GS and Hayward SD: A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat Med 9: 300-306, 2003.

51. Bouskrioua Y, Yang Y, Zampieri CA and Alwayne JC: The TORtral affairs of viruses: Effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathway. Nat Rev Microbiol 6: 266-275, 2008.

52. Gaglia MM and Munger K: More than just oncogenes: Mechanisms of tumorigenesis by human viruses. Curr Opin Virol 32: 48-59, 2018.

53. Imamichi H, Smith M, Adelsberger JW, Izumi T, Scrimieri F, Gaglia MM and Munger K: More than just oncogenes: Mechanisms of tumorigenesis by human viruses. Curr Opin Virol 32: 48-59, 2018.

54. Takahashi M, Kawai K and Asai N: Roles of the RET proto-oncogene in cancer and development. JMA J 3: 175-181, 2020.

55. Wang H, Boussouar A, Mazelin L, Tauszig-Delamasure S, Sun Y, Huang SY and Xiao Y: Molecular mechanism of tumorigenesis by human viruses. Curr Opin Virol 32: 48-59, 2018.

56. Avanzi S, Alvisi G and Ripalti A: How virus persistence can facilitate proto-oncogene c-Myc translation via dissociating Raf family members and the impact on oncogenic Ras signalling. Spencer-Smith R, Esposito D, Zhou Y, Hancock JF, Kortum RL: c-Kit inhibits tumor growth by behaving as a dependence receptor. Mol Cell 72: 413-425.e5, 2018.

57. Huang P, Wang CH, Zhuo LY, Xia XS, Yang S, Zhang JW, Peters S, Ponce S, Fernández C, Alfaro V, Azman AS, Reich NG and Lessler J: The incubation period of SARS-CoV-2 infection and monocyte response through a HIF-1alpha-dependent axis. Cell Metabol 32: 498-499, 2020.

58. Defrancesco I, Zerbi C, Rattotti S, Merli M, Bruno R, Paulli M: Determinants of COVID-19 disease severity in patients with cancer. Nat Med 126: 1218-1223, 2020.

59. Lewis WD, Lilly S and Jones KL: Lymphoma: Diagnosis and treatment. Am Fam Physician 101: 34-41, 2020.

60. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Shi J, Zhou M, Wu B, Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huisings K, Brar I, Alangaden GI, Ramesh MS, McKinnon JE, et al: Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis 97: 396-403, 2020.

61. Johnson KM, Belfier JJ, Peterson GR, Boekhuis MR and Dumkow LE: Managing COVID-19 in renal transplant recipients: A review of recent literature and case supporting corticosteroid-sparing immunosuppression. Pharmacotherapy 40: 517-524, 2020.

62. Singh AK, Majumdar S, Singh R and Misra A: Role of corticosteroid in the management of COVID-19: A systematic review and a Clinician's perspective. Diabetes Metab Syndr 14: 971-978, 2020.

63. Luo P, Liu Y, Qiu L, Liu X, Liu D and Li J: Tocilizumab treatment in COVID-19: A single center experience. J Med Virol 92: 814-818, 2020.

64. Wooding DJ and Bach H: Treatment of COVID-19 with convalescent plasma: Lessons from past coronavirus outbreaks. Clin Microbiol Infect 26: 1436-1446, 2020.

65. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, et al: Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 epidemic in China. Cancer Discov 10: 2383-2391, 2020.

66. Li D, Liu C, Liu J, Hu J, Yang Z and Zhou H: Analysis of risk factors for 24 patients with COVID-19 developing from moderate to severe condition. Front Cell Infect Microbiol 10: 548582, 2020.

67. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Shi J, Zhou M, Wu B, Yang Z, et al: Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 146: 110-118, 2020.

68. Turquin C, Ryan BM, Horikawa I, Harris BT and Harris CC: Determination and case supporting corticosteroid-sparing immunosuppression. Biochimie 180: 2020.

69. Lewis WD, Lilly S and Jones KL: Lymphoma: Diagnosis and treatment. Am Fam Physician 101: 34-41, 2020.

70. Raymond E, Thieblemont C, Alran S and Faivre S: Impact of the COVID-19 outbreak on the management of patients with cancer. Target Oncol 15: 249-259, 2020.

71. Robilotti EV, Bahady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, Bogler Y, Caldararo M, Figueroa CJ, Glickman MS, et al: Determinants of COVID-19 disease severity in patients with cancer. Nat Med 126: 1218-1223, 2020.

72. Turnquist C, Ryan BM, Horikawa I, Harris BT and Harris CC: Determination and case supporting corticosteroid-sparing immunosuppression. Biochimie 180: 2020.
108. Shang J, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, Lu H, Liu J, Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, Lu H, Liu J, Yang J, Dong Y, et al: Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: A multicentre, retrospective, cohort study. Lancet Oncol 21: 904-913, 2020.

109. Pinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng C, Salazar R, Bertuzzi A, Brunet J, Mesia R, Segui E, et al: Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer Discov 10: 1465-1474, Jul 31, 2020. (Epub ahead of print) 10.1158/2159-8290.CD-20-0773.

110. Mihalopoulos M, Dogra N, Mohamed N, Badani K and Mihalopoulos M, Dogra N, Mohamed N, Badani K and Pravettoni G, Mazzocco K, Houssami N, Pagani O, Senkus E: Profiles Drug Subst Excip Relat Methodol 45: 93-117, 2020.

111. Li G, Hu R and Zhang X: Antihypertensive treatment with ACEi/ARB of patients with COVID-19 complicated by hypertension. Hypertens Res 43: 588-590, 2020.

112. Rico-Mesa JS, White A and Anderson A5: Outcomes in patients with COVID-19 infection taking ACEI/ARB. Curr Cardiovasc Risk Rep 4: 21-50, 2020.

113. De Spiegeleer A, Brunselaer A, Teixeiro L, Goedegebuure SP, Ellsworth S, Garcia D, et al: Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: Interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis 50: 72-81, 2021.

114. Li et al: CORRELATION OF SARS-CoV-2 TO CANCER: CARCINOGENIC OR ANTICANCER?
131. Dhar D and Mohanty A: Gut microbiota and Covid-19-possible link and implications. Virus Res 285: 198018, 2020.
132. Bottari B, Castellone V and Neviani E: Probiotics and Covid‑19. Int J Food Sci Nutr 72: 293‑299, 2021.
133. Annweiler G, Corvaisier M, Gauthier J, Dubée V, Legrand E, Sacco G and Annweiler C: Vitamin D supplementation associated to better survival in hospitalized frail elderly COVID‑19 patients: The GERIA‑COVID quasi‑experimental study. Nutrients 12: 3377, 2020.
134. Jeon SM and Shin EA: Exploring vitamin D metabolism and function in cancer. Exp Mol Med 50: 1‑14, 2018.
135. Munshi R, Hussein MH, Toraih EA, Elshazli RM, Jardak C, Sultana N, Youssef MR, Omar M, Attia AS, Fawzy MS, et al: Vitamin D insufficiency as a potential culprit in critical COVID‑19 patients. J Med Virol 93: 733‑740, 2021.
136. Carpagnano GE, Di Lecce V, Quaranta VN, Zito A, Buonamico E, Capozza E, Palumbo A, Di Gioia G, Valerio VN and Resta O: Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID‑19. J Endocrinol Invest 44: 765‑771, 2021.
137. Shakoor H, Feehan J, Al Dhaheri AS, Ali HI, Platat C, Ismail LC, Apostolopoulos V and Stojanovska L: Immune‑boosting role of vitamins D, C, E, zinc, selenium and omega‑3 fatty acids: Could they help against COVID‑19? Maturitas 143: 1‑9, 2021.
138. Thakkar A, Gonzalez‑Lugo JD, Goradia N, Galí R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica RA, et al: Seroconversion rates following COVID‑19 vaccination among patients with cancer. Cancer Cell 39: 1081‑1090.e2, 2021.
139. Rodriguez Socarrás M, Gómez Rivas J, Teoh JY, Puente J, Moschini M and Moreno‑Sierra J: The Uro‑oncology patient and vaccination against SARS‑CoV‑2. Eur Urol Open Sci 29: 77‑81, 2021.
140. Duijf PHG: Low baseline pulmonary levels of cytotoxic lymphocytes as a predisposing risk factor for severe COVID‑19. mSystems 5: e00741‑20, 2020.
141. Challenor S and Tucker D: SARS‑CoV‑2‑induced remission of Hodgkin lymphoma. Br J Haematol 192: 415, 2021.

This work is licensed under a Creative Commons Attribution‑NonCommercial‑NoDerivatives 4.0 International (CC BY‑NC‑ND 4.0) License.